Thalidomide in cancer: potential uses and limitations.

Area of Science:

• Oncology
• Pharmacology

Background:

• Thalidomide possesses immunomodulatory, cytokine-modulatory, and antiangiogenic properties.
• Its therapeutic potential has been explored across multiple cancer types, including multiple myeloma, myelodysplastic syndromes, and others.

Purpose of the Study:

• To review the efficacy and safety of thalidomide in various cancers.
• To highlight its role in multiple myeloma and myelodysplastic syndromes.

Main Methods:

• Review of existing clinical data and trials involving thalidomide in cancer treatment.
• Analysis of response rates and adverse effects across different malignancies.

Main Results:

• Thalidomide shows remarkable activity in multiple myeloma, with significant responses in both early and pretreated patients.
• It improves cytopenias in myelodysplastic syndromes, reducing transfusion dependence.
• Responses observed in Kaposi's sarcoma, renal cell carcinoma, glioma, and colon cancer, often in combination therapies.

Conclusions:

• Thalidomide is a valuable therapeutic option for multiple myeloma, particularly in relapsed or refractory cases.
• It offers benefits for myelodysplastic syndromes and other cancers, warranting further investigation in clinical trials.
• While side effects are common, severe adverse events requiring treatment cessation are infrequent.